We have further demonstrated that the inhibition of TGF-β enhances anti-CTLA-4 antibody treatment in an autochthonous melanoma model, and that delayed inhibition of TGF-β, but not initial combinatorial therapy, improves anti-PD-1 antibody responses by reversing adaptive resistance (142). The gene discussed is CTLA4; the disease is melanoma.